Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 4/20 | 0.53 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | SLC5A7 | Q9GZV3 | 2/20 | 0.46 |
| ▸ | GPR6 | P46095 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5656041 | 0.83 | CCR3 (0.75) | CCR3SSTR5KCNH2HRH1SLC5A7 | |
| Hydrochloric Acid SCHEMBL5658393 | 0.81 | CCR3 (0.57) | CCR3HRH1SLC5A7POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5658390 | 0.78 | CCR3 (0.67) | CCR3SSTR5KCNH2HRH1SLC5A7 | |
| SCHEMBL4071895 | 0.78 | DRD3 (0.53) | POLB | |
| SCHEMBL3073489 | 0.78 | DRD3 (0.53) | POLB | |
| SCHEMBL6402130 | 0.76 | CCR3 (0.78) | CCR3KCNH2HRH1SLC5A7HTR7 | |
| SCHEMBL5656798 | 0.76 | CCR3 (0.53) | CCR3KCNH2HRH1SLC5A7 | |
| Hydrochloric Acid SCHEMBL6396476 | 0.75 | CCR3 (0.77) | CCR3KCNH2HRH1SLC5A7HTR7 | |
| SCHEMBL5657206 | 0.75 | CCR3 (0.73) | CCR3KCNH2HRH1SLC5A7POLB | |
| SCHEMBL5655951 | 0.74 | CXCR4 (0.48) | CCR3SLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304077-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-12-04 | — | — | US | disclosed |
| US-20040102432-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1322611-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002020484-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102432-A1 | Chemical compounds | CCL11, HRH1, HRH4 | CCR3 17/4885SSTR5 399/4885KCNH2 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.